Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the reduction in these symptoms over the long term, and improve patients’ functional capacity. Schizophrenia is a highly drug-treated condition that uses an array of antipsychotic medications, including atypical and typical antipsychotic drugs, resulting in a complex treatment algorithm. Although the drug market is entrenched with generic therapies, the need for longer-acting, more-effective, and more-tolerable drugs gives branded agents (e.g., Janssen’s Invega Trinza, Intra-Cellular Therapies’ Caplyta, Indivior’s Perseris, AbbVie’s Vraylar) the opportunity to be incorporated into the treatment algorithm. As such, understanding the treatment dynamics, with the presence of both long-established and newer-to-market branded drugs, will be crucial for drug developers and marketers of in-line products to understand physicians’ prescribing behavior in schizophrenia.
QUESTIONS ANSWERED
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Geography: United States
Real world data: Longitudinal patient-level claims data analysis
Key companies: AbbVie, Alkermes, Janssen, Indivior, Intra-Cellular Therapies, Lundbeck, Otsuka, Sumitomo Dainippon Pharma / Sunovion Pharmaceuticals, Noven Pharma
Key drugs covered: Invega Sustenna, Invega Trinza, Abilify Maintena, Aristada, Risperdal Consta, Latuda, Rexulti, Vraylar, Perseris, Caplyta, Secuado, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, typical antipsychotics, other generics
Key analysis provided